Open to Global Participation, More than 100 Attendees in First Q & A
SUNRISE, FL – Feb. 12, 2018 – Dr. Kristin Comella, Chief Science Officer of U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the successful launch of an open, livestream webinar series designed to inform and educate the public on the benefits and applications of stem cell therapy.
“Facts About Stem Cell Therapy,” which had its first live broadcast last Friday and includes a question & answer session from more than 100 patients and physicians around the world, continued for nearly two hours while live streamers posted questions to Dr. Comella about the application of autologous stem cells therapy. Such a strong, positive response demonstrates the growing demand for information about this emerging, holistic, regenerative therapy.
Playback of the webinar can be accessed here:
Dr. Comella will be hosting a second livestream webinar Saturday, Feb. 17, at 12 noon EST (Click here to register). In honor of Valentine’s Day and the month of love, her featured guest will be fitness expert Ben Greenfield, who recently underwent stem cell therapy for erectile enhancement — a multi-million-dollar industry that is increasing in patient population but is underserved, mainly due to side effects associated with erectile dysfunction pharmaceuticals currently on the market.
“The webinar platform gives us the perfect opportunity to make the concept of autologous stem cell therapy accessible to the world,” said Dr. Comella. “It also enables audience participation in a manner that allows for privacy. I read the questions to the audience, so we maintain privacy from the inquisitor while simultaneously providing the opportunity for a comprehensive teaching moment, even in playback. It’s a perfect way to help people learn more about this incredible form of healing.”
Dr. Comella, who has more than 20+ years’ experience and is one of the world’s leading stem cell scientists, is also featured in the recent Jeff Hays docuseries “The Healing Miracle: The Truth About Stem Cells.” (Click here to view Dr. Comella’s interview from THM in its entirety.) It was her participation in the docuseries that inspired her to launch the webinar series.
“Dr. Comella is a natural — her passion is contagious and her expertise in stem cell therapy is unparalleled,” said Mike Tomas, Chief Executive Officer of U.S. Stem Cell, Inc. “Because demand has been so strong at our clinics, as more and more people are learning about stem cell therapy as an alternative to pain management, the webinar format gives us the opportunity to reach more people faster, and to meet the demand for more specific information in a really efficient and effective way.”
USRM has been involved in more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases. USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 287 clinics. Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies. She has also been instrumental in developing and bringing to market USRM’s AdipocellTM, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.